A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy
CAPTURE
1 other identifier
interventional
600
1 country
1
Brief Summary
The purpose of this study is to develop and implement a critical pathway to identify patients with ischemic cardiomyopathy who are candidates for an implantable cardioverter-defibrillator (ICD). This study will also determine whether the use of the critical pathway for ICDs is associated with a change in the ICD referral and implantation rate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2012
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2010
CompletedFirst Posted
Study publicly available on registry
November 25, 2010
CompletedStudy Start
First participant enrolled
April 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedMarch 7, 2012
March 1, 2012
1 month
November 22, 2010
March 6, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rate of Referral for ICD Assessment
1 year
Secondary Outcomes (1)
Rate of ICD Implantation
1 year
Study Arms (2)
Critical Pathway
EXPERIMENTALStandard Practice
NO INTERVENTIONInterventions
The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
Eligibility Criteria
You may qualify if:
- acute ST segment elevation myocardial infarction (STEMI)
- candidate for percutaneous revascularization
- permanent residents of British Columbia, Canada
You may not qualify if:
- patients with heart disease or a comorbid illness who have a documented life expectancy of less than 1 year
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
S Cowan, MD, MSc
St. Paul's Hospital, Vancouver, British Columbia
- STUDY DIRECTOR
A Ignaszewski, MD
St. Paul's Hospital, Vancouver, British Columbia
- PRINCIPAL INVESTIGATOR
C Kerr, MD
St. Paul's Hospital, Vancouver, British Columbia
- STUDY DIRECTOR
S Tung, MD
St. Paul's Hospital, Vancouver, British Columbia
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2010
First Posted
November 25, 2010
Study Start
April 1, 2012
Primary Completion
May 1, 2012
Study Completion
May 1, 2012
Last Updated
March 7, 2012
Record last verified: 2012-03